Zhengye Biotechnology (ZYBT) Competitors $9.32 +0.11 (+1.19%) As of 09/12/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock ZYBT vs. APGE, CDTX, BEAM, BHVN, TWST, IMCR, AUPH, TVTX, ARDX, and WVEShould you be buying Zhengye Biotechnology stock or one of its competitors? The main competitors of Zhengye Biotechnology include Apogee Therapeutics (APGE), Cidara Therapeutics (CDTX), Beam Therapeutics (BEAM), Biohaven (BHVN), Twist Bioscience (TWST), Immunocore (IMCR), Aurinia Pharmaceuticals (AUPH), Travere Therapeutics (TVTX), Ardelyx (ARDX), and WAVE Life Sciences (WVE). These companies are all part of the "pharmaceutical products" industry. Zhengye Biotechnology vs. Its Competitors Apogee Therapeutics Cidara Therapeutics Beam Therapeutics Biohaven Twist Bioscience Immunocore Aurinia Pharmaceuticals Travere Therapeutics Ardelyx WAVE Life Sciences Zhengye Biotechnology (NASDAQ:ZYBT) and Apogee Therapeutics (NASDAQ:APGE) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their profitability, dividends, analyst recommendations, media sentiment, earnings, institutional ownership, risk and valuation. Does the media prefer ZYBT or APGE? In the previous week, Apogee Therapeutics had 10 more articles in the media than Zhengye Biotechnology. MarketBeat recorded 12 mentions for Apogee Therapeutics and 2 mentions for Zhengye Biotechnology. Zhengye Biotechnology's average media sentiment score of 1.37 beat Apogee Therapeutics' score of 1.21 indicating that Zhengye Biotechnology is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Zhengye Biotechnology 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Apogee Therapeutics 8 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has stronger valuation & earnings, ZYBT or APGE? Zhengye Biotechnology has higher revenue and earnings than Apogee Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioZhengye Biotechnology$25.53M17.22$1.55MN/AN/AApogee TherapeuticsN/AN/A-$182.15M-$4.13-8.93 Is ZYBT or APGE more profitable? Zhengye Biotechnology's return on equity of 0.00% beat Apogee Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Zhengye BiotechnologyN/A N/A N/A Apogee Therapeutics N/A -34.65%-32.76% Do institutionals and insiders hold more shares of ZYBT or APGE? 79.0% of Apogee Therapeutics shares are held by institutional investors. 42.8% of Apogee Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth. Do analysts recommend ZYBT or APGE? Apogee Therapeutics has a consensus target price of $97.29, suggesting a potential upside of 163.79%. Given Apogee Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Apogee Therapeutics is more favorable than Zhengye Biotechnology.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Zhengye Biotechnology 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Apogee Therapeutics 0 Sell rating(s) 1 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.88 SummaryApogee Therapeutics beats Zhengye Biotechnology on 6 of the 11 factors compared between the two stocks. Get Zhengye Biotechnology News Delivered to You Automatically Sign up to receive the latest news and ratings for ZYBT and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ZYBT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ZYBT vs. The Competition Export to ExcelMetricZhengye BiotechnologyMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$434.40M$3.20B$5.87B$10.14BDividend YieldN/A2.30%5.68%4.59%P/E RatioN/A21.1774.5225.93Price / Sales17.22476.06548.33126.97Price / Cash89.3846.6837.5660.44Price / Book9.149.6112.166.29Net Income$1.55M-$53.29M$3.28B$270.77M7 Day Performance13.80%0.28%0.87%3.88%1 Month Performance10.95%5.73%4.96%4.88%1 Year PerformanceN/A10.52%60.74%26.01% Zhengye Biotechnology Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ZYBTZhengye BiotechnologyN/A$9.32+1.2%N/AN/A$434.40M$25.53M0.00278News CoverageAPGEApogee Therapeutics2.9008 of 5 stars$37.86+4.1%$97.29+157.0%-25.0%$1.68BN/A-9.1791News CoveragePositive NewsCDTXCidara Therapeutics3.2669 of 5 stars$63.79-2.4%$64.14+0.6%+478.1%$1.66B$1.27M-5.7390Positive NewsBEAMBeam Therapeutics2.8529 of 5 stars$16.31-0.3%$48.45+197.1%-15.6%$1.66B$63.52M-3.62510BHVNBiohaven3.2663 of 5 stars$15.89+3.2%$54.23+241.3%-61.0%$1.63BN/A-2.07239Trending NewsTWSTTwist Bioscience3.98 of 5 stars$26.24-2.7%$49.40+88.3%-43.2%$1.63B$312.97M-18.10990News CoverageIMCRImmunocore1.8525 of 5 stars$32.26+0.1%$56.89+76.3%+6.7%$1.62B$310.20M-80.65320AUPHAurinia Pharmaceuticals2.9484 of 5 stars$11.68-2.6%$12.00+2.7%+93.6%$1.58B$235.13M27.16300News CoveragePositive NewsTVTXTravere Therapeutics2.9769 of 5 stars$18.15+3.7%$33.43+84.2%+86.3%$1.56B$233.18M-8.90460News CoveragePositive NewsAnalyst ForecastARDXArdelyx4.6258 of 5 stars$6.40+0.6%$11.50+79.7%+6.3%$1.53B$333.61M-27.8290Positive NewsWVEWAVE Life Sciences4.481 of 5 stars$9.62+0.2%$20.27+110.7%+18.9%$1.53B$108.30M-10.69240Positive News Related Companies and Tools Related Companies APGE Alternatives CDTX Alternatives BEAM Alternatives BHVN Alternatives TWST Alternatives IMCR Alternatives AUPH Alternatives TVTX Alternatives ARDX Alternatives WVE Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ZYBT) was last updated on 9/13/2025 by MarketBeat.com Staff From Our PartnersHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored“Sell Nvidia before earnings”Eric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | SponsoredNvidia Times 1,000,000Nvidia’s latest AI chip is a $25,000 powerhouse — with 80 billion transistors and the ability to perform 60 tr...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Zhengye Biotechnology Holding Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Zhengye Biotechnology With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
